# Biotech Growth Trust reports 16.5% annual share price return as NAV rises 16%

- Link: https://www.directorstalkinterviews.com/biotech-growth-trust-reports-16-5-annual-share-price-return-as-nav-rises-16/4121269904
- Published: 2026-11-16T14:08:00+00:00
- Author: Amilia Stone

**Biotech Growth Trust PLC** (LON:BIOG) has announced its Fact Sheet as at 31 October
2026 is now available.

**Commentary**

In October, the NAV per share was -7.4%, the share price was -10.9% and the benchmark
NASDAQ Biotechnology Index (net, total return, sterling adjusted) was +1.9%.

During October, broader equity markets experienced a sharp sell-off in technology
stocks and a rotation towards more defensive sectors, including healthcare. Despite
generally resilient corporate earnings, investor scrutiny intensified around the
significant capital being deployed towards artificial intelligence infrastructure
and whether these investments will generate adequate returns.

Within biotechnology, the defensive rotation resulted in strength in the large cap
names, with smaller biotechnology companies continuing to face significant selling
pressure. Volatility in the 10-year Treasury yield remained high as well, exacerbating
this divergence given that small cap stocks are more sensitive to interest rate 
volatility. The Company’s overweighting in small caps and underweighting in large
caps resulted in significant underperformance versus the benchmark.

Another factor impacting the Company’s performance was a significant reduction in
the gross exposure of biotech positions by hedge funds. Morgan Stanley reported 
that the most crowded biotech longs were being sold and the most crowded biotech
shorts were being bought during the month. This degrossing meant that many of the
companies we consider high quality that hedge funds held long suffered the largest
share price declines, while many of the lower quality companies that had been popular
shorts outperformed as funds covered their short positions. Given that the Company
held many of these popular longs, this degrossing effect artificially depressed 
the share prices of many of those names. In light of these developments, the Company
took a more defensive posture, reducing small and mid cap names in the portfolio
and increasing our exposure to large caps. We continue to believe that as 10-year
Treasury yields stabilise, shares of small and mid-cap biotech companies will eventually
recover from these transiently depressed levels.

Following the month end, the U.S. midterm elections delivered a sweeping Democratic
victory, with Democrats taking decisive control of both chambers of Congress. It
is unclear what Democrats will be able to achieve legislatively given that President
Trump is likely to veto many of their proposed bills. However, it is possible that
there will be some headline noise for the biopharmaceutical industry in 2027 if 
Democrats propose new policies to lower drug prices in the U.S. We do not expect
any meaningful changes to drug pricing in the medium term but will continue to monitor
the political situation.

[biog-factsheet-october-2026](https://www.directorstalkinterviews.com/wp-content/uploads/2026/11/biog-factsheet-october-2026.pdf)
[Download](https://www.directorstalkinterviews.com/wp-content/uploads/2026/11/biog-factsheet-october-2026.pdf)

_**Biotech Growth Trust plc** (LON:BIOG) seeks capital appreciation through investment
in the worldwide biotechnology industry. The Company and the Company’s Portfolio
Manager believe that there is a high congruence between companies that seek to act
responsibly and those that succeed in building long-term shareholder value. _

Share on:
